Retinoid X Receptor as a Therapeutic Target to Treat Neurological Disorders Associated with α-Synucleinopathy
Cells · 2025
DOI: 10.3390/cells14100685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Assylbek Zhylkibayev und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Retinoid X Receptors, Synucleinopathies. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, M. J. Fox Foundation, National Eye Institute.
Abstract (Originalsprache)
This study investigated the therapeutic potential of the nuclear retinoid X receptor (RXR) in mitigating the progression of alpha-synucleinopathies (αSNPs), particularly in Parkinson’s disease (PD). PD-like pathology in mice was successfully induced through the co-delivery of AAV expressing human α-synuclein (αS) and αS preformed fibrils (PFFs) into the substantia nigra pars compacta (SNpc). Significant increases in Lewy body (LB)-like inclusions, loss of tyrosine hydroxylase-positive (TH+) neurons, and reductions in dopamine (DA) levels in the striatum were observed. Additionally, diminished levels of PPARα and NURR1—proteins essential for neuronal survival—along with elevated expression of IBA1 and GFAP, markers of microglial activation and astrocytic gliosis, respectively, are associated with the pathogenesis of Parkinson’s disease. AAV-mediated overexpression of human RXRα demonstrated preservation of TH+ neurons, prevention of DA decline, and attenuation of αS accumulation. Furthermore, RXR-treated PD brains showed a reduced number of GFAP+ and Iba1+ cells, decreased GFAP+ and IBA1+ immunoreactivity, and fewer and less widespread LB-like aggregates. RXR overexpression also enhanced the production of PPARα and NURR1. These findings suggest that RXRα upregulation promotes neuroprotection by mitigating αSNPs and chronic neuroinflammation, a major contributor to PD progression. This research underscores the therapeutic potential of targeting nuclear receptors, such as RXR, in neurodegenerative diseases like PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, School of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA.
- Department of Ophthalmology, School of Medicine, University of Alabama, Birmingham, AL 35233, USA.
- Department of Pharmacology and Toxicology, School of Medicine, University of Alabama, Birmingham, AL 35294, USA.
- Department of Neurology, School of Medicine, University of Alabama, Birmingham, AL 35205, USA.
- Department of Dermatology, Heersink School of Medicine, University of Alabama, Birmingham, AL 35233, USA.
- Department of Translational Neuroscience, School of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA.
ORCID-Profile: Assylbek Zhylkibayev, Christopher R Starr, M Iqbal Hossain, Venkatram R Atigadda, Marina S Gorbatyuk
Förderung
- NEI NIH HHS
- M. J. Fox Foundation
- National Eye Institute
Zitieren
APA
Zhylkibayev, A., Starr, C. R., Hossain, M. I., Kumar, S., Andrabi, S. A., Grant, M. B., Atigadda, V. R., Gorbatyuk, M. S., & Gorbatyuk, O. S. (2025). Retinoid X Receptor as a Therapeutic Target to Treat Neurological Disorders Associated with α-Synucleinopathy. Cells. https://doi.org/10.3390/cells14100685
Vancouver
Zhylkibayev A, Starr CR, Hossain MI, Kumar S, Andrabi SA, Grant MB, et al. Retinoid X Receptor as a Therapeutic Target to Treat Neurological Disorders Associated with α-Synucleinopathy. Cells. 2025. doi:10.3390/cells14100685
BibTeX
@article{Zhylkibayev2025,
author = {Zhylkibayev, Assylbek and Starr, Christopher R and Hossain, M Iqbal and Kumar, Sandeep and Andrabi, Shaida A and Grant, Maria B and Atigadda, Venkatram R and Gorbatyuk, Marina S and Gorbatyuk, Oleg S},
title = {Retinoid X Receptor as a Therapeutic Target to Treat Neurological Disorders Associated with α-Synucleinopathy},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14100685}
}
EUVIMED